Shamburg News · 8-K filed Nov 10, 2026, 4:07 PM EST

Metagenomi Reports Q3 2026 Results and FDA IND Clearance for MGX-001 Hemophilia A Program

MGX · Metagenomi Therapeutics, Inc.

  • Earnings
  • Other event
  • Materiality: high

Metagenomi Therapeutics furnished a press release reporting third quarter 2026 results and announcing FDA clearance of its IND application for MGX-001, its lead hemophilia A program. The company reported a net loss of $21.1 million, or $0.56 per share, for the quarter ended September 30, 2026, versus $20.4 million, or $0.55 per share, a year earlier. Cash, cash equivalents and available-for-sale marketable securities were $101.7 million at September 30, 2026, with runway anticipated into 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-455436.

Written from the filing by Shamburg Markets. Figures are as reported by the company.